Detailed Narrative
Q1 FY27 Combined Entity Performance Highlights
The newly merged Aster DM Quality Care Limited delivered a strong Q1 FY27 on a proforma basis, with revenue increasing 20% year-on-year to INR 2,597 crores. EBITDA grew 30% YoY to INR 576 crores, resulting in an EBITDA margin of 22.2%, an expansion of 170 basis points YoY. Patient volumes exceeded 2 million, marking a 13% YoY increase, while blended occupancy reached 64%, up 510 basis points YoY. Medical Value Travel (MVT) revenue also saw significant growth of 62% YoY.
Strategic Pillars and Post-Merger Integration
The company's strategic focus post-merger is built on three pillars: scaling super-specialty care in high-acuity domains like Oncology, Neurosciences, and Cardiac Sciences; expanding geographic access by introducing advanced clinical protocols to Tier 2 and Tier 3 markets; and driving patient-centric innovation through digital health platforms. The integration process, marked by an enterprise-wide #GOGREATER celebration, aimed for zero operational friction and cultural alignment across the 45,000-strong team.
Synergy Potential and Operational Efficiency
Management anticipates significant synergies from the merger, targeting 10%-15% incremental EBITDA, which are expected to start playing out this financial year and annualize into the next. The operational execution speed was highlighted by the Kasargod facility, which achieved EBITDA breakeven in June 2026, within just 9 months of operation. This demonstrates the company's ability to rapidly ramp up newly commissioned facilities to profitability.
Capacity Expansion and New Projects
Aster DM Quality Care has a robust expansion roadmap to add over 4,170 beds in the next 3 to 4 years, increasing total capacity to over 15,000 beds, with 53% being brownfield-led. Key upcoming projects include the Trivandrum hospital, expected to be operational in H2 FY27 (likely January), the Hyderabad hospital in April 2027 (beginning of FY28), and Phase I of the Sarjapur hospital in H2 FY28. The 159-bed Aster Women & Children block at Aster Whitefield was commissioned in April 2026 and is already seeing strong patient traction.
Regional Performance and Maturity-Based Reporting
The Kerala region demonstrated strong recovery with 25% revenue growth (20% excluding Kasaragod), driven by a 16% increase in IP volumes and 19% in OP volumes. Karnataka, which experienced doctor attrition in previous quarters, recovered to 16% growth in Q1 FY27, with all three Bangalore hospitals (Aster CMI, Aster Whitefield, Aster RV) achieving their highest-ever revenue. The company is shifting towards a maturity-based reporting framework, categorizing assets as Mature (73% of revenue, targeting 25% EBITDA), Focus (under-delivering, targeting improvement), Emerging (new hospitals, rapid ramp-up), and Underperforming (smallest bucket, requiring surgical intervention).
Aster DM Healthcare and Quality Care Standalone Performance (Q1 FY27)
For the Aster DM Healthcare platform, revenue increased 22% YoY to Rs. 1,311 Cr, with operating EBITDA growing 29% to Rs. 277 Cr, and operating EBITDA margin expanding 117 basis points to 21.1%. Normalised PAT (excluding exceptional costs📎) rose 39% YoY to Rs. 125 Cr. The Quality Care platform delivered 19% YoY revenue growth to INR 1,287 Cr, with operating EBITDA surging 32% YoY to 299 Cr, and margin expansion of 216 bps to 23.2%. Its occupancy jumped 656 bps to 65.4%, and ARPP IP reached ~INR 144k.